Valuation: Cipher Pharmaceuticals Inc.

Market Cap 428M 305M 265M 247M 227M 29.11B 434M 2.91B 1.14B 14.49B 1.15B 1.12B 48.59B P/E 2026 *
13.7x
P/E 2027 * 12.2x
Enterprise Value 428M 305M 265M 247M 227M 29.11B 434M 2.91B 1.14B 14.49B 1.15B 1.12B 48.59B EV / Sales 2026 *
5.85x
EV / Sales 2027 * 5.06x
Free-Float
57.64%
Yield 2026 *
-
Yield 2027 * -
1 day+3.40%
1 week+1.99%
1 month+1.51%
3 months-9.53%
6 months+11.81%
Current year+8.77%
1 week 11.43
Extreme 11.43
11.94
1 month 11.43
Extreme 11.43
12.37
Current year 10.11
Extreme 10.1101
15
1 year 8.92
Extreme 8.92
15
3 years 2.5
Extreme 2.5
15
5 years 1.06
Extreme 1.06
15
10 years 0.3
Extreme 0.3028
15
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Change 5-day change 1-year change 3-year change Capi.($)
+3.40%+1.99% - - 305M
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
Average -0.85%-1.21%+26.03%+42.41% 379.88B
Weighted average by Cap. -1.00%-2.02%+36.14%+71.90%

Financials

2026 *2027 *
Net sales 73.13M 52.13M 45.31M 42.18M 38.72M 4.98B 74.26M 497M 195M 2.48B 196M 191M 8.31B 84.52M 60.25M 52.37M 48.75M 44.76M 5.75B 85.83M 575M 226M 2.86B 226M 221M 9.6B
Net income 30.44M 21.7M 18.86M 17.56M 16.12M 2.07B 30.91M 207M 81.23M 1.03B 81.5M 79.71M 3.46B 36.1M 25.73M 22.37M 20.82M 19.11M 2.46B 36.65M 245M 96.31M 1.22B 96.63M 94.51M 4.1B
Net Debt - -
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-07-31 US$11.94 +3.40% 2,388
26-07-30 US$11.55 -0.94% 5,747
26-07-29 US$11.66 -.--% 4,101
26-07-28 US$11.66 +0.52% 3,150
26-07-27 US$11.60 -0.94% 1,960
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.83CAD
Average target price
20.64CAD
Spread / Average Target
+22.62%

Quarterly revenue - Rate of surprise